BACKGROUND: Recently, using the @entity1 's genotype to guide @entity1229 dosing has gained interest; however, whether @entity1297 ( @entity1297 ) improves clinical outcomes compared to @entity7617 ( @entity7617 ) remains unclear. Thus, we performed a meta-analysis to evaluate these two strategies. METHODS: The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese @entity3549 and Chinese Wan-fang databases were searched. The Cochrane Collaboration's tool was used to assess the risk of bias in randomized controlled trials (RCTs). The primary outcome was time within the therapeutic range (TTR); the secondary end points were the time to maintenance dose and time to first therapeutic international normalized ratio (INR), an INR greater than 4, adverse events, major @entity548 , @entity1031 and @entity204 from any cause. RESULTS: A total of 11 trials involving 2,678 @entity1 were included in our meta-analysis. The results showed that @entity1297 did not improve the TTR compared to @entity7617 , although @entity1297 significantly shortened the time to maintenance dose ( @entity601 = -8.80; 95% CI: -11.99 to -5.60; P<0.00001) and the time to first therapeutic INR ( @entity601 = -2.80; 95% CI: -3.45 to -2.15; P<0.00001). Additionally, @entity1297 significantly reduced the risk of adverse events (RR = 0.86; 95% CI: 0.75 to 0.99; P = 0.03) and major @entity548 (RR = 0.36; 95% CI: 0.15 to 0.89, P = 0.03), although it did not reduce the percentage of INR greater than 4, the risk of @entity1031 and @entity204 from any cause. Subgroup analysis showed that @entity1297 resulted in a better improvement in the endpoints of TTR and over-anticoagulation at a fixed initial dosage rather than a non-fixed initial dosage. CONCLUSIONS: The use of genotype testing in the management of @entity1229 anticoagulation was associated with significant improvements in INR-related and clinical outcomes. Thus, genotype-based regimens can be considered a reliable and accurate method to determine @entity1229 dosing and may be preferred over fixed-dose regimens. TRIAL REGISTRATION PROSPERO: Database registration: CRD42015024127.

Pharmacogenetics-Based versus Conventional Dosing of XXXX : A Meta-Analysis of Randomized Controlled Trials.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity7617 :: ('MESH:C563514', 'Disease') :: ['CD', 'conventional dosing'] @entity3549 :: ('7432', 'Gene') :: ['VIP'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1297 :: ('MESH:D019292', 'Disease') :: ['pharmacogenetics-based dosing', 'PD'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism', 'thromboembolic events'] @entity601 :: ('MESH:D009436', 'Disease') :: ['MD'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1229 :: (MESH:D014859,Chemical) :: ['Warfarin']
